Ladenburg analyst Matthew Kaplan downgraded Eyenovia (EYEN) to Neutral from Buy without a price target citing the negative MicroPine interim analysis.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYEN:
- Eyenovia downgraded to Neutral from Buy at H.C. Wainwright
- Eyenovia downgraded to Market Perform from Outperform at William Blair
- Eyenovia downgraded to Hold from Buy at Brookline
- Eyenovia plans to terminate Phase 3 CHAPERONE study after DRC review
- Eyenovia price target lowered to $4.50 from $7 at Ladenburg